Paediatric patients with moderate-to-severe Covid-19 will be enrolled in a late-stage study testing the effects of remdesivir in children.
Remdesivir is an antiviral medicine that was being developed for the treatment of Ebola. Its maker, Gilead Sciences, has been working with researchers and governments and conducting clinical trials for the drug. On June 18, Gilead announced that they are ready to conduct a Phase II/III clinical trial of remdesivir to treat paediatric patients hospitalised with Covid-19. They further said that they will assess the 'safety, tolerability, pharmacokinetics and efficacy' of the drug in around 50 paediatric patients with moderate-to-severe Covid-19, including newborns and adolescents. The trial is expected to be completed by December 2020.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.